HER2-low breast cancer accounts for approximately 60% of HER2-negative breast cancer cases [2, 3].T-DXd is an antibody–drug conjugate with a payload of the topoisomerase I inhibitor deruxtecan (DXd, an exatecan derivative) bound to an anti-HER2 antibody. This evidence concerns the gene ERBB2 and breast carcinoma.